Blueberry Therapeutics receives clearance from the FDA to proceed with the clinical investigation of BB2603
February 3, 2020 | FDA, clinical trials, drug development, nano technology
Blueberry Therapeutics has received an investigational new drug (IND) clearance from the Food and Drug Administration (FDA) to proceed with the clinical development of BB2603
Alderley Park, UK, January 2020
Blueberry Therapeutics has received an investigational new drug (IND) clearance from the Food and Drug Administration (FDA) to proceed with the clinical development of BB2603 for the treatment of onychomycosis.
The IND is a crucial milestone in the continued development of BB2603, a nanoformulated, topical form of terbinafine for the treatment of onychomycosis (fungal toenail). With the IND in place the company has initiated a Phase IIb international, multicentre double-blinded study.
The primary outcome of this study is to look at the efficacy BB2603 in onychomycosis, with a secondary dose finding outcome also being investigated.
John Ridden, CEO said: “Having received clearance from the FDA we are looking forward to the opportunity to work with over 20 international sites on the Phase IIb trial of BB2603 with the first patient expected to be recruited in March 2020.This is a key milestone in our path to commercialisation of our nanotechnology product portfolio.”
With BB2603, Blueberry Therapeutics aim to maintain the efficacy of the oral gold standard treatment, but at a lower dose. Delivering the active pharmaceutical ingredient using nanotechnology ensures it penetrates across the nail plate and reaches the target site of action in a controlled manner, meaning lower doses can be used and systemic side effects are minimised.
ENDS
Blueberry Therapeutics Limited Media Contact
Elle Bell – Onyx Health
ebell@onyxhealth.com
Tel: +44 (0) 191 640 3638
Notes to Editors
About Blueberry Therapeutics Limited
Blueberry Therapeutics Ltd., incorporated in November 2011, is a drug discovery and development company focused on developing innovative nanomedicines for difficult to treat skin and nail infections. The company is using its state-of-the-art nanotechnology to develop high value medicines where a reduced dose and improved drug delivery is needed, to overcome existing efficacy, tolerability and safety profile concerns.
Blueberry Therapeutics combines expert in-house resources with selected outsource partners and collaborators to take projects through from preclinical research onto de-risked human clinical proof of concept and then on to the market. For more information, please visit http://www.blueberrytherapeutics.com
This content was provided by Onyx Health
Company Details
Latest Content from Onyx Health
Onyx Health Announces Two Top Appointments
Onyx health have made two senior appointments to their communications team
Onyx Health Marks Record Growth with Six New Appointments
Onyx Health has expanded its communications team with six new appointments, after more than doubling its fee incomes and expanding its international client portfolio over the past year
Onyx Health Launch Creative Studio After Record Year
Healthcare marketing communications specialists Onyx Health have set up a new creative studio following a year of record income growth and international client expansion.
PulmoBioMed Wins National Life Science Competition
Newly launched Northumbria University spinout PulmoBioMed has been handpicked as the winners of Onyx Health's ThinkBig competition
Licensing Deal for NP213 Nail Fungus Treatment is Another Key Milestone for NovaBiotics
Leading biotechnology company NovaBiotics Ltd have secured a major licensing deal for their fungal nail treatment
Newcells Biotech secures over £5m for 3D tissue models
Newcells Biotech have received multi-million investment to develop their pioneering 3D tissue models
Onyx Health Targets Digital Growth with New Executive Director
Healthcare marketing communications agency Onyx Health have appointed Trevor Pill as their new Executive Director
Onyx Health Launch National Competition for Life Science SMEs
Healthcare marketing communications agency Onyx Health are launching a national competition #ThinkBig to help health and life sciences SMEs bounce back from the COVID-19 crisis
Onyx Health Celebrates Its 10th Anniversary with Five New Hires
Onyx Health have marked their 10th anniversary by welcoming five new members to their rapidly expanding team. These appointments come on the back of the agency’s continued growth throughout the...
Lifesaving QR Code Wearable Launched to Help Emergency Services
MedTech company Mavin Informatics have just launched mi-SOS, a lifesaving QR code-based medical identity wearable across the UK